Vicore obtains significant new patent protection for C21 in the US
Stockholm, May 23, 2023 – Vicore Pharma Holding AB (STO:VICO) (“Vicore”) today announces issuance of a new US patent protecting an improved C21 formulation based on enteric coated compositions. The drug candidate C21 is currently in a phase 2a trial in idiopathic pulmonary fibrosis (IPF).
The patent provides strong protection in the US because the granted patent claims:
- relate to any form of enteric coating of C21; and
- are not limited to any specific disease
